News & Events

In the News

  • Microbiotica reports positive phase Ib data for live microbiome therapeutic
    11 February  2026
    BioWorld

    View Item

     

     

  • COMPOSER-1 trial makes sweet music for Microbiotica
    11 February  2026
    Business Weekly

    View Item

     

     

  • Microbiotica’s microbiome therapy showed 63% remission in ulcerative colitis phase 1b trial
    11 February  2026
    European Biotechnology Magazine

    View Item

     

     

  • Ulcerative Colitis Microbiome Treatment Succeeds in Phase Ib Trial
    11 February  2026
    Inside Precision Medicine

    View Item

     

     

  • Cambridge, UK based Microbiotica announced results from a phase 1b trial of its microbiome treatment MB310 in ulcerative colitis showing a 63% remission rate
    18 February  2026
    Biotech TV

    View Item

     

     

  • Unravelling the modes of action of microbiome therapies
    19 September 2025
    Drug Discovery World

    View Item

     

     

  • Meet the teams behind the cancer research breakthroughs 
    18 July 2025
    The Telegraph

    View Item

     

     

  • Microbiotica
    14 January 2025
    Business Weekly

    View Item

     

     

  • Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease
    14 November 2024
    BiotechTV

    Watch here

     

     

  • Microbiotica begins human trials for ulcerative colitis treatment
    13 November 2024
    PharmaTimes

    View item

  • The Life Sci Fantastic Podcast: Bugs For Drugs?
    31 October 2024
    Our CEO Tim Sharpington and CSO Trevor Lawley join Eliot Forster on The Life Sci Fantastic Podcast

    Listen here

  • Microbiotica entering clinic with live bacterial therapeutics
    27 August 2024
    BioWorld

    View item

  • Could microbiome drugs be the key to unlocking checkpoint inhibitors’ potential?
    27 August 2024
    Labiotech

    View item

  • Novel biotherapeutic to be tested in ulcerative colitis
    26 February 2024
    Medscape Medical news

    View item

  • Microbiotica: transforming medicine with microbiome magic
    24 October 2023
    Drug Target Review

    View item

  • Microbiotica and Merck collaborate on skin cancer trial
    19 April 2023
    Business Weekly

    View item

  • Microbiotica, MSD partner to start melanoma combo therapy trial
    13 April 2023
    Clinical Trials Arena

    View item

  • How to have a healthy gut
    18 March 2023
    The Guardian Supplement

    View item

  • Microbiome-based therapies as anti-cancer agents
    14 September 2022
    Mednous

    View item

  • Microbiome Modulators Slowly Nurture Investor Confidence
    29 March 2022
    Scrip

    View full story [Behind a paywall]

  • Microbiome space in spotlight as Microbiotica sets funding record
    11 March 2022
    Labiotech.eu

    View item

  • Microbiotica raises £50m for microbiome-based discovery pipeline
    10 March 2022
    Cambridge Independent

    View full story

  • Microbiotica advancing bacterial signature to improve immunotherapy response, patient selection
    10 March 2022
    Precision Oncology News

    View item

  • Microbiotica nabs $67M to push 2 microbiome therapies through clinic
    7 March 2022
    Fierce Biotech

    View full story

  • Good gut bacteria helps immune system resist Covid-19, says Microbiotica
    12 June 2020
    Cambridge Independent

    View full story

  • Genentech’s immunology/infectious disease deal maker on following the science
    7 November 2018
    Scrip

    View full story [Behind a paywall]

  • How Microbiotica is getting closer to a blueprint of your body’s bacteria
    29 June 2018
    Cambridge Independent

    View full story

  • Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD
    29 June 2018
    Labiotech

    View full story

  • Genentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs
    6 June 2018
    Fierce Biotech

    View full story